The traditional molecular companion diagnostic always needs to be based on tissue specimens. As a new tumor marker, ctDNA plays an important role in the areas such as individualized tumor medication detection and recurrence and therapy efficacy monitoring. First, ctDNA-based liquid biopsy can be an effective supplement to biopsy, for it can largely reduce the sufferings and risks brought by collection of specimens to the patients receiving first- or second-line tumor therapy, especially to the advanced-stage cancer patients from whom the biopsy specimens cannot be acquired; Second, ctDNA-based liquid biopsy can genuinely restore the panorama of tumor, for ctDNA may be released into the peripheral blood by all tumor focus (including primary focus and metastasis focus) due to the spatial tumor heterogeneity which leads to an inaccurate reflection of the panorama of tumor by biopsy; And last, ctDNA-based liquid biopsy can actualize dynamic blood collecting at different time point, actualize dynamic monitoring in tumor therapy process, and may discover the occurrence of drug-resistance molecular mechanism earlier than imaging, while biopsy cannot monitor in real time the tumor evolvement and drug resistance due to the temporal tumor heterogeneity.
Advantages of the peripheral blood circulating tumor DNA (ctDNA) detection
1) Applicable to the patients who cannot tolerate a biopsy, and a substitute for risky invasive specimen detection;
2) Will not be limited by focus position and cancer type;
3) Capable of avoiding the problem of tissue specimen heterogeneity, and can genuinely reflect the overall view of gene variation in patients;
4) Actualize a dynamic monitoring of therapy efficacy and disease progress.
Liquid biopsy is one of the top ten breakthrough techniques in 2015 released by MIT Technology Review. Specialist consensus on liquid biopsy is reached at the 13th lung Cancer Summit Forum in March 2016; It is pointed out by the specialist consensus that "the consensus three【the NGS method is recommended in detection, by liquid biopsy, of multiple known targets which can be inhibited clinically by medication in parallel】, and the consensus four 【the NGS method is suggested to use in liquid biopsy for discovering of unknown gene, exploring of the therapy efficacy monitoring, prediction of prognosis and discovering of the drug resistance mechanism and so on】". Liquid biopsy has wide application prospects in precise tumor therapy.
Next generation sequencing-based ctDNA liquid biopsy can actualize a parallel multi-gene detection of multiple targets, having very high sensitivity and specificity. Burning Rock Dx launches two non-invasive gene detection products for individualized tumor medication—"Lungplasma" and “Lung core（blood version）”for the patients with non-small-cell lung carcinoma and "Pureplasma" for the patients with other solid tumors.
Lung cure™-The Blood Version
Burning Rock Lung cure™–the blood version, developed for the patients with advanced-stage non-small-cell lung carcinoma, can detect the 8 genes recommended by NCCN Guidelines all at once, based on the peripheral blood ctDNA as detection specimen and on the advanced technique of targeted sequencing plus next generation sequencing, covering all targeting medicines for non-small-cell lung carcinoma approved by FDA and cFDA, and can provide precise and comprehensive reference information for the formulation of a personalized therapy plan for the clinical first-line patients with non-small-cell lung carcinoma from whom sufficient tissue specimens cannot be acquired.